证券代码：002940 证券简称：昂利康 公告编号：2025-102 浙江昂利康制药股份有限公司（以下简称"昂利康"或"公司"）子公司浙 江昂利康医药销售有限公司（以下简称"昂利康医药销售"）于 2025 年 12 月 12 日以现金方式收到一笔与收益相关的政府补助资金 1,047.1 万元，占公司最近 一期经审计的归属于上市公司股东净利润的 13.03%。现将具体情况公告如下： 一、获取补助的基本情况 单位：人民币元 | 获得补助 | 补助金额 | 收到补助时间 | | | 补助类型 | 是否与公司日常 | 是否具有 | | --- | --- | --- | --- | --- | --- | --- | --- | | 的主体 | | | | | | 经营活动相关 | 可持续性 | | 昂利康医 | 10,471,000 | 2025 年 月 12 | 12 | 日 | 与收益相 | 是 | 否 | | 药销售 | | | | | 关 | | | 二、补助的类型及对上市公司的影响 1、补助的类型 浙江昂利康制药股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整 ...

Core Viewpoint - Recently, the company announced that it has received the drug registration certificate for Diclofenac Sodium Enteric-coated Tablets and the approval notice for the supplemental application of Sacubitril/Valsartan Tablets from the National Medical Products Administration [2] Group 1 - The company has been granted a drug registration certificate for Diclofenac Sodium Enteric-coated Tablets [2] - The company has also received an approval notice for the supplemental application of Sacubitril/Valsartan Tablets [2]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

Core Viewpoint - Company received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for the supplemental application of Sacubitril/Valsartan Tablets from the National Medical Products Administration [1] Group 1: Product Approvals - Diclofenac Sodium Enteric-Coated Tablets are indicated for inflammatory and degenerative rheumatic diseases, various non-articular soft tissue rheumatic pain, acute gout attacks, acute mild to moderate pain, and as an adjunct treatment for severe pain infections in the ear, nose, and throat [1] - Sacubitril/Valsartan Tablets are indicated for the treatment of chronic heart failure in adults with reduced ejection fraction and for primary hypertension [1] Group 2: Collaboration and Market Launch - The Sacubitril/Valsartan Tablets were developed in collaboration with Suzhou Pengxu Pharmaceutical Technology Co., Ltd. and Suzhou Jingyun Pharmaceutical Technology Co., Ltd. [1] - The 200mg formulation of Sacubitril/Valsartan Tablets is set to be approved for market launch in June 2024, and the company has received approval for an additional 100mg specification [1]

昂利康公告称，近日收到国家药监局签发的双氯芬酸钠肠溶片《药品注册证书》和沙库巴曲缬沙坦钠片 《药品补充申请批准通知书》。双氯芬酸钠肠溶片规格25mg，批准文号有效期至2030年12月8日，视同 通过一致性评价；沙库巴曲缬沙坦钠片增加100mg规格，批准文号有效期至2029年6月27日。此次获批 将丰富公司产品管线及规格，但药品销售受政策、市场等因素影响，存在不确定性。 ...

Core Insights - The company Anglikon (002940) has received regulatory approvals for two pharmaceutical products, enhancing its product pipeline and specifications [1] Group 1 - The company announced the receipt of a drug registration certificate for Diclofenac Sodium Enteric-Coated Tablets [1] - The company also received a supplemental approval notice for Sacubitril/Valsartan Sodium Tablets in the 100mg specification [1] - These approvals are expected to further enrich the company's product offerings [1]

证券代码：002940 证券简称：昂利康 公告编号：2025-101 | 药品通用名称 | 双氯芬酸钠肠溶片 | | | --- | --- | --- | | 主要成份 | 双氯芬酸钠 | | | 剂型 | 片剂 | | | 申请事项 | 药品注册（境内生产） | | | 注册分类 | 化学药品 类 4 | | | 规格 | 25mg | | | 受理号 | CYHS2402146 | | | 药品批准文号 | 国药准字 H20256225 | | | 药品批准文号有效期 | 至 2030 12 月 08 日 | 年 | | 上市许可持有人 | 名称：浙江昂利康制药股份有限公司 | | | | 地址：浙江省嵊州市嵊州大道北 号 1000 | | | 生产企业 | 名称：浙江昂利康制药股份有限公司 | | | | 地址：绍兴市嵊州市嵊州大道北 号 1000 | | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准注册，发 | | | | 给药品注册证书。 | | （一）药品注册证书主要内容 （二）药品补充申请批准通知书 1 | 药品通用名称 | 沙库巴曲 ...

目前国内医药生产企业众多，竞争较为激烈，昂利康始终坚持将研发作为企业的核心发展动力，注重业 内合作，立足于开发具有临床价值的优质产品。经过多年的发展，在口服头孢类抗生素原料药、alpha 酮酸原料药、心血管类制剂、吸入用麻醉原料药、抗雄性激素中间体及植物源胆固醇系列产品上均具有 显著优势。公司是国内最早掌握酶法技术的口服头孢类原料药生产厂家之一；公司是国内最大的alpha 酮酸原料药生产厂家，也是费森尤斯卡比的核心原料药供应商之一；公司是国内钙拮抗剂类抗高血压制 剂的主要生产企业之一，苯磺酸左氨氯地平片在国内市场具有较高的市场占有率；公司是国内主要的吸 入用麻醉原料药和制剂一体化的生产企业；公司是国内较早以植物甾醇生物发酵所得产品为起始原料生 产甾体药物中间体的企业，是国内首家实现植物源胆固醇规模化生产的企业，在抗雄性激素中间体、植 物源胆固醇、植物源维生素D系列等细分领域已取得行业领先地位。 此次入选两项榜单，既是对昂利康创新工作的肯定，也将激励企业继续前进。未来，昂利康将继续坚持 研发投入，加强专利布局，推动更多优质医药产品上市，为浙江省民营经济高质量发展贡献力量，助力 公众健康事业发展。 昂利康主要从事 ...

智通财经APP讯，昂利康(002940.SZ)公告，公司收到国家药品监督管理局签发的恩格列净二甲双胍缓释 片(II)《药品注册证书》。恩格列净二甲双胍缓释片(II)是恩格列净和盐酸二甲双胍的复方制剂，适用于 正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。 ...

Core Viewpoint - The company, Anglikang (002940.SZ), has received a drug registration certificate from the National Medical Products Administration for its drug, Ertugliflozin Metformin Extended-Release Tablets (II), indicating a significant advancement in its product portfolio for diabetes treatment [1] Group 1: Drug Approval Details - The drug is a combination formulation of Ertugliflozin and Metformin Hydrochloride, aimed at improving blood sugar control in adult patients with type 2 diabetes who are already receiving treatment with these medications [1] - The company received the acceptance notice for the drug's marketing authorization application in June 2024 and has recently obtained approval from the National Medical Products Administration [1] - The issuance of the drug registration certificate is considered equivalent to passing the consistency evaluation as per national policy regulations [1]